AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05309187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202
Description: IO-202 given as monotherapy
Study NCT05309187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IO-202 + pembrolizumab combination therapy
Description: IO-202 and fixed dose pembrolizumab combination therapy
Study NCT05309187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types
Description: Expansion cohorts of the RP2D of IO-202 and fixed dose pembrolizumab combination therapy in multiple tumor types.
Study NCT06183840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glutack
Description: Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Glutack
Study NCT06183840 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Three ports are used (1x11 mm and 2x5 mm) and after adhesiolysis and the field prepared, the defect is measured with a local standard in a craneo-caudal and transversal directions. Then, the defect is closed with a 2-0 caliber barbed suture following its biggest axis. A Dynamesh IPOM previously hydrated (2-3 min) is introduced throughout the 11mm trocar and extended. After this maneuver, mesh fixation is performed depending on the randomized arm: Traumatic fixation
Study NCT05885100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eleveld Model
Description: Target plasma propofol
Study NCT04639583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) utilization
Description: The NIRS devise will be applied so that cerebral regional oxygen saturation (cRSO2) can be measured.
Study NCT05348174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Assisted Guided Imagery (VRAGI)
Description: The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.
Study NCT05348174 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality Assisted Guided Imagery (VRAGI)
Description: The visual landscape consists of a computer-generated immersive virtual world with nature-based imagery (i.e., trees, birds, mountains, water) and accompanying soundscapes with guided imagery.
Study NCT06240832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy exercise
Description: Endurance, strength and stretching training in Chronic liver disease children
Study NCT05195294 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LioCyx-M
Description: HBV antigen specific TCR redirected T cells
Study NCT05195294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg once daily for patients ≥60 kg, 8 mg for patients \<60kg by oral
Study NCT05957991 — intervention group
Intervention type: DRUG
Intervention: Metformin Hydrochloride tablet
Description: Treatment with metformin
Study NCT05957991 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Treatment with placebo
Study NCT05957991 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle intervention
Description: Changing behaviour on diet and excersise
Study NCT05957991 — intervention group
Intervention type: BEHAVIORAL
Intervention: No lifestyle intervention
Description: No changes in behaviou on diet and excersise
Study NCT05462015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: elastic-band exercises
Description: The training content includes 5 minutes of warm-up exercise, 20 minutes of elastic-band resistance training, and 10 minutes of cool-down exercise.
Study NCT05462015 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: regular rehabilitation
Description: The training content includes 5-minute warm-up exercise, 20-minute upper and lower extremity muscle strengthening, and 10-minute cool-down exercise
Study NCT04919642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT-00420
Description: TT-00420 tablet, administered orally once daily
Study NCT05989906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Description: Participants will undergo 1:1 therapist supervised SIT for 10 minutes per day, three times per week during IPR using a Monark 881 arm crank ergometer.
Study NCT05989906 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will have the opportunity to participate in optional group endurance exercise classes two to three times a week.
Study NCT05989906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Ergometer (ERGO)
Description: Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery.
Study NCT05989906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Participants complete the SIT intervention during IPR and be provided with a consumer-grade ergometer. Study staff will train the participants in the set-up and use of the home ergometer prior to discharge and arrange for take home or delivery. These participants will also receive weekly Motivational Interviewing (MI) counseling sessions during IPR plus six post-discharge MI sessions delivered via telehealth to be held over six months.
Study NCT05500209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal resources' enhancement: self-efficacy
Description: Participants in this condition are asked to take part in a 7-day psychological intervention delivered through Facebook Messenger chat-bot. Each day one CBT-framed exercise aimed at coping self-efficacy enhancement is delivered. An exercise takes form 5 to 30 minutes to complete.
Study NCT04875546 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Adolescent will receive a brief smoking cessation intervention based on the '5A' and '5R' models. Then the research assistant will ask about their tobacco use and assist them to quit using the STAR method. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
Study NCT04875546 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Intervention
Description: In addition to the brief smoking cessation intervention based on the '5A' and '5R' models, the participants will receive brief advice on alcohol use based on the FRAMES model. Then the RA will invite participants to complete the Alcohol Use Disorders Identification Test and provide personalized feedback. There will be a one to one, 20-30 minutes semi-structured interviews with 30 participants. Participants with high(N=15) and low (N=15) adherence will be purposively selected. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
Study NCT04875546 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The adolescents will receive the leaflets for smoking cessation and alcohol abstinence. A booster intervention will be given over the phone at 1-week, 1month, 3-month, and 6 month follow-up.
Study NCT05914142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proton radiation therapy
Description: Radiation: Proton Therapy System (ProBeam)
Study NCT05379348 — intervention group
Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Montreal Cognitive Assessment - MoCA, which is a cognitive screening tool that assesses: memory, concentration, language, and orientation to time and place. this written cognitive test should take no more than 20 minutes.
Study NCT05023096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco product administration and assessment
Description: Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
Study NCT05023096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco product administration and assessment
Description: Participants are first instructed to smoke their usual brand of menthol cigarettes normally for the next 7 days and avoid using any other tobacco products. After this baseline week, participants are randomized to 1 of 3 ENDS flavor conditions, all contain 5% nicotine (Mentol+Tobacco, Tobacco, Unflavored) with equal probability and provided with a supply of their condition specific ENDS and asked to use it in place of their usual menthol cigarettes for the next 6 weeks.
Study NCT06496815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib will be taken orally twice a day, 0.2g each time.
Study NCT06496815 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy
Description: Eligible subjects will receive transhepatic arterial embolization chemotherapy or hepatic arterial infusion chemotherapy as previous (if have).
Study NCT06496815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1,PD-L1
Description: PD-1/PD-L1 will be used as previous (if have).
Study NCT05063227 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Observational: analgesia monitoring indices and changes in heart rate
Description: After the end of surgery (defined as the time of skin closure or wound dressing), but before awakening (BIS will still be \< 60), SPI, PPI and NOL are recorded in a quiet setting without any other stimulation. Within the five minutes data acquisition period nociception indices are recorded every minute (T0, T1, T2, T3, T4, T5). The highest SPI, PPI and NOL are used for further analysis.
Study NCT05169151 — intervention group
Intervention type: OTHER
Intervention: Smartphone Application
Description: Utilize smartphone application
Study NCT04936360 — intervention group
Intervention type: OTHER
Intervention: questionnaires for clinical assessments
Description: questionnaires for clinical assessments
Study NCT05269485 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose fractionated radiotherapy
Description: Patients in this arm would receive high-dose fractionated radiotherapy with 60-68Gy/15-17f with one-year immunotherapy maintenance.
Study NCT05269485 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose fractionated radiotherapy
Description: Patients in this arm would receive high-dose fractionated radiotherapy with 48Gy/15-12f with one-year immunotherapy maintenance.
Study NCT00105651 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combined nursing invention
Study NCT04558866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: One administration every 63 cycles until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
Study NCT04558866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: During 4 weeks, from day 29 to day 56 of each 63-day cycle (+- 3 days) until progression or unacceptable toxicity or completion of treatment phase (54 weeks; 6 cycles), whichever comes first.
Study NCT06141369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: individualized mRNA neoantigen vaccine (mRNA-0523-L001)
Description: Individualized mRNA neoantigen vaccine (mRNA-0523-L001) will be injected intramuscularly every 21 days for 9 cycles. Dose escalation will be administered in 3 patients. 18 additional patients will be recruited and administered at the maximum tolerated(MTD) dose for all nine cycles.
Study NCT06039124 — intervention group
Intervention type: OTHER
Intervention: bevacizumab treatment
Description: Descriptive study of HHT patients (bevacizumab treatment, number of RBC transfused)
Study NCT06177964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lerapolturev
Description: Lerapolturev (intratumoral) will be dosed at 2x108 TCID50 in 3.0 mL x 2 doses (total dose 4x108 TCID50) by Convection Enhanced Delivery.~For the patients randomized to the lerapolturev Arm 1 of Stage 2, seven days (±2 days) following completion of the 2nd intratumoral infusion of lerapolturev, patients will begin cervical perilymphatic subcutaneous injection of lerapolturev at a dose of 2 x 108 TCID50 (in 0.5 ml diluent) around the cervical lymph node chain ipsilateral to the intracranial tumor.
Study NCT06177964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine Pill
Description: Lomustine will be given as a single oral dose of 110 mg/m2 every six weeks for up to 9 cycles.
Study NCT06068270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-ostoperforations (MOPs)
Description: 3 MOPs will be performed in the bone next to the root of the experimental tooth. MOPs will be performed using the Excellerator® (Propel Orthodontics, Denstply, Sirona)
Study NCT06306625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: A brachial cuff is positioned around one arm of the patient. Remote ischemic conditioning consists of four cycles of a 5-min brachial cuff inflation at 200 mmHg followed by a 5-min of cuff deflation, and is started as soon as possible after randomization. The intervention is repeated 12 and 24 hours after inclusion.
Study NCT06306625 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: No remote ischemic conditioning
Description: A brachial cuff is positioned around the arm of the patient and no inflation or deflation is performed.
Study NCT04729673 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)
Description: Measuring the vertical distance between the gingival zenith of the upper canine to the gingival zenith of the lower canine
Study NCT04729673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital caliper (Shenzhen Jiabaili Electronic Commerce Co., Ltd)
Description: Measuring the vertical distance between the gingival zenith of the upper canine to the gingival zenith of the lower canine
Study NCT05068570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARMEROMTERY
Description: ARMERGOMTERY TRAINING FOR UPPERLIMB
Study NCT05214859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Dyadic Expressive Arts Group Therapy
Description: This therapy utilizes different art modalities, such as visual art, music, movement, dance, drama, and writing, as therapeutic means. With multiple sensory stimulations from different art forms, the therapy facilitates communication, expression, perception, and interactions. The therapy consists of 8 weekly 90 minutes sessions, with 3-4 mother-child dyads in each therapy group. Each session will follow the basic structure of Expressive Arts Therapy, including check-in, warm-up, core art-making, sharing, and closure. The following themes related to the mother-child relationship will be included, such as communication, relationship, expression, empathy, interaction, love, gratitude, and connection.
Study NCT05873998 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Slow pressure-volume curve
Description: Patients will be sequentially subjected to a slow pressure-volume curve and a lung recruitment maneuver
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wen Xin granule
Description: one dose daily, two times per day.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: one tablet daily. (for patients who can't use aspirin)
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: one tablet daily. (for patients who can't use aspirin)
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin Calcium
Description: 20 mg tablet, one tablet each night.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: 20 mg tablet, one tablet each night.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: one tablet， twice daily.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate Tab 20 MG
Description: one tablet， twice daily.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg, two times daily.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol Tartrate Tab 25 MG
Description: 12.5 mg or 25 mg, two times daily.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets
Description: 100mg tablet, one tablet daily.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets
Description: 100mg tablet, one tablet daily.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WXG placebo
Description: one dose daily, two times per day.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine Dihydrochloride Tablets
Description: 20 mg tablet, one tablet three times daily.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glyceryl trinitrate
Description: be taken when angina pectoris attacks.
Study NCT04661709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyceryl trinitrate
Description: be taken when angina pectoris attacks.
Study NCT04944511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab Injection
Description: Toripalimab Injection used for mixed chimerism between 80%-95% in HLH patients. Dose: 240mg toripalimab Injection, two weeks later, the same dose will be repeated if patients have some improve in the chimeric rate.
Study NCT04639973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Group 1 (First trimester ultrasound)
Description: A detailed first trimester anatomy ultrasound will be performed,at the visit when the subject is confirmed to be of eligible gestational age. After this detailed research ultrasound, which will be limited to 15 minutes, subject will then receive the clinically indicated dating ultrasound or nuchal translucency measurement. The patient will complete a survey about her satisfaction with this technique via email.as a safety measure, if an anomaly is suspected on the day of the detailed first trimester anatomy scan, the patient will be unblinded. Patients in this arm are later scheduled for a second trimester ultrasound by the clinical team, as this is part of standard obstetrical care.
Study NCT04639973 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 (Second trimester anatomy ultrasound)
Description: Patients do not undergo a detailed first trimester ultrasound , but will receive the clinically indicated limited ultrasound for dating or for nuchal translucency. Patient will then undergoes a second trimester ultrasound by the clinical team as part of standard obstetrical care and completes a survey regarding her satisfaction with this technique via email.
Study NCT05744089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCA pump
Description: simple hydromorphone PCA pump model, which is a rapid titration followed by a convenient maintenance technique, to treat home cancer patients with severe or critical cancer pain or refractory cancer pain.
Study NCT05073614 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: immunohistochemical detection of Heparanase in chronic gastritis
Description: immunohistochemical detection of Heparanase in chronic gastritis specimens.
Study NCT05435651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multitask game-based digital therapy
Description: To practice multitask-game on the system for approximately 25 minutes/day at least 5 days a week.
Study NCT05435651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Schulte Grid digital game
Description: To practice Schulte Grid digital game on the system for approximately 25 minutes/day at least 5 days a week.
Study NCT05778058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unilateral Stimulation
Description: With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
Study NCT05778058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilateral Stimulation
Description: With the Vagustim device, vagus nerve stimulation will be applied in one ear for 20 minutes, with a frequency of 10 Hz, a pulse width of 300 μs in Modulation mode, and a constant current that the participant will feel the current comfortably.
Study NCT05778058 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bilateral Sham Stimulation
Description: Participants were shown that the device was working, but no current was given.